Zoetis Inc.
NYSE:ZTSDrug Manufacturers - General
+$1.17 today
- Market cap
- $34.76B
- Beta
- 0.74
- P/E (TTM)
- 12.5
- EPS (TTM)
- $6.26
- Dividend yield
- 2.63%
Volume 4.66M
Average 6.20M
ZTS Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Zoetis Inc.NYSE: ZTS
Research & Development · Q2 FY2026 · quarter ended Jun 2026
Research & development grows, but more slowly than its trailing trend
Q2 FY2026 research & development of $173M rose 0.6% year over year, behind the +5.9% change in trailing-twelve-month research & development. Sequentially, it fell 3.9% from the prior quarter. Over 3 fiscal years it compounded at +9.0% a year.
Context
- Research & development amounted to 7.4% of revenue in FY2025, unchanged from a year earlier.
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +0.6% toward the trailing-twelve-month pace of +5.9%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 698M USD
- Year-over-year change
- +1.7%
- 4-year CAGR
- +8.3%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 698M | +1.7% |
| FY2024 | 2024-12-31 | 686M | +11.7% |
| FY2023 | 2023-12-31 | 614M | +13.9% |
| FY2022 | 2022-12-31 | 539M | +6.1% |
| FY2021 | 2021-12-31 | 508M | — |
Research & Development vs competitors
How ZTS compares with its peers on the latest reported figures
- ZTS's LTM Jun 2026 research & development of $722M is the 2nd highest of the 6 companies compared; the peer median is $266.87M.
- Its year-over-year change of +5.9% is the 4th highest of 5, against a peer median of +8.6%.
- Research & development amounts to 7.6% of revenue for ZTS, versus a peer median of 5.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $28.35B | +65.7% | -2.6% | 42.7% | |
| LTM Jun 2026 | $722M | +5.9% | +9.0% | 7.6% | |
| LTM Sep 2026 | $381M | +7.0% | +4.7% | 7.4% | |
| LTM Sep 2026 | $266.87M | +10.2% | -0.5% | 5.7% | |
| LTM Aug 2026 | $19.76M | -5.9% | -10.9% | 2.2% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding ZTS) | $266.87M | +8.6% | -1.5% | 5.7% | |
Competitors are the stored peer set for ZTS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 7.78B | 8.08B | 8.54B | 9.26B | 9.47B |
| Cost of Revenue | 2.46B | 2.6B | 2.71B | 2.86B | 2.79B |
| Gross Profit | 5.31B | 5.48B | 5.83B | 6.4B | 6.67B |
| Gross Margin | 68.3% | 67.8% | 68.3% | 69.1% | 70.5% |
| Research & Development | 508M | 539M | 614M | 686M | 698M |
| Selling, General & Admin | 2B | 2.01B | 2.15B | 2.32B | 2.38B |
| Operating Expenses | 2.51B | 2.55B | 2.77B | 3B | 3.08B |
| Depreciation & Amortization | 448M | 465M | 491M | 497M | 487M |
| EBITDA | 3.17B | 3.36B | 3.69B | 3.87B | 4.07B |
| EBITDA Margin | 40.8% | 41.6% | 43.1% | 41.8% | 43.0% |
| Operating Income | 2.8B | 2.93B | 3.07B | 3.39B | 3.6B |
| Operating Margin | 36.0% | 36.2% | 35.9% | 36.6% | 38.0% |
| Interest Income | 6M | 50M | 105M | 106M | 93M |
| Interest Expense | 236M | 237M | 258M | 242M | 243M |
| Other Income / Expenses | (315M) | (272M) | (133M) | (259M) | (237M) |
| Income Before Tax | 2.49B | 2.66B | 2.94B | 3.13B | 3.36B |
| Pre-Tax Margin | 32.0% | 32.9% | 34.4% | 33.8% | 35.5% |
| Income Tax Expense | 454M | 545M | 596M | 637M | 687M |
| Net Income | 2.04B | 2.11B | 2.34B | 2.49B | 2.67B |
| Net Margin | 26.2% | 26.2% | 27.4% | 26.9% | 28.2% |
| EPS (Basic) | 4.29 | 4.51 | 5.08 | 5.47 | 6.03 |
| EPS (Diluted) | 4.27 | 4.49 | 5.07 | 5.47 | 6.02 |
| Weighted Avg Shares | 474.35M | 468.89M | 461.17M | 454.2M | 443.44M |
| Weighted Avg Shares (Diluted) | 476.72M | 470.39M | 462.27M | 454.85M | 443.84M |
Zoetis Inc.
NYSE:ZTS
Intrinsic Alpha fair value
Locked
Current Price
$85.55
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.